Acadia Pharmaceuticals Inc Expected To Post Earnings Of 18 Cents A Share: Earnings Preview

Acadia Pharmaceuticals

03/08/2024 24:18

* ACADIA Pharmaceuticals Inc  ACAD.OQ   ACAD.O  is expected
to show a rise in quarterly revenue when it reports  results on
August 6 for the period ending June 30 2024
    * The San Diego California-based  company is expected to
report a
42.5% increase in revenue to $235.418 million from $165.24
million a year ago, according to the mean estimate from 18
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for ACADIA Pharmaceuticals
Inc is
for earnings of 18 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 15 "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 1.7%
in the last three months. ​
    * Wall Street's median 12-month price target for ACADIA
Pharmaceuticals Inc is $28.00​, above​ its last closing price
of $18.77. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  0.04        0.05       0.10      Beat    113.7
 Dec. 31 2024  0.29        0.30       0.28      Missed  -7.9
 Sep. 30 2023  -0.43       -0.43      -0.40     Beat    6.1​
 Jan. 1 0001   -0.03       -0.08      0.01      Beat    112.1
 ​​Mar.        -0.21       -0.21      -0.27     Missed  -25.8
 31 2023                                                
 Dec. 31 2022  -0.24       -0.24      -0.26     Missed  -7​
 Sep. 30 2022  -0.20       -0.19      -0.17     Beat    10.3
 Jun. 30 2022  -0.24       -0.25      -0.21     Beat    15.2
 This summary was machine generated August 2 at 23:18 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)